Castle Biosciences, Inc. - CSTL STOCK NEWS

Castle Biosciences (CSTL) announced a collaboration with the National Cancer Institute (NCI) to link its DecisionDx-Melanoma test data with the SEER Program's melanoma case registry. Initial findings show that DecisionDx-Melanoma significantly improves overall survival rates in patients aged 65+ when compared to untested individuals. This data, presented at the 2022 Winter Clinical Dermatology Conference, indicates that patients tested with DecisionDx-Melanoma have a 34% lower risk of death, enhancing the test's clinical relevance. Future collaborations aim to include more recent data.

Castle Biosciences (NASDAQ: CSTL) will showcase its skin cancer diagnostic tests at Maui Derm for Dermatologists 2022 from January 24-28, 2022, in Maui, Hawaii. Key presentations include the integration of a 31-gene expression profile for melanoma risk assessment and the appropriate use of a 40-gene expression profile test for cutaneous squamous cell carcinoma. The DecisionDx-Melanoma and DecisionDx-SCC tests aim to enhance patient management by predicting metastatic risks. These tests have been validated in numerous studies, indicating their reliability in clinical settings.

Castle Biosciences (CSTL) announced a clinical performance study published in Future Oncology, showcasing the DecisionDx-SCC test's ability to independently assess metastasis risk in patients with cutaneous squamous cell carcinoma (SCC).

The study involved 420 cases and revealed significant stratification of risk, with metastasis rates of 6.6%, 20.0%, and 52.2% for Class 1, 2A, and 2B results, respectively. The findings suggest that integrating DecisionDx-SCC enhances risk prediction for individualized patient management.

Castle Biosciences, Inc. (CSTL) announces the publication of a study validating the DecisionDx-UMSeq panel, enhancing uveal melanoma diagnostics. This 7-gene test leverages next-generation sequencing to identify critical somatic mutations from a single biopsy. Results show 100% positive agreement for single nucleotide variants and high technical prediction values. The combined use of DecisionDx-UM, DecisionDx-PRAME, and DecisionDx-UMSeq allows for comprehensive tumor profiling, aiding in better-informed patient care and management decisions.

Castle Biosciences (CSTL) expects 2021 revenue to meet or exceed $93 million. The company delivered 28,118 gene expression profile test reports in 2021, a 55% increase from the previous year. Notable fourth-quarter performance included 8,242 reports, with 5,635 DecisionDx-Melanoma reports (up 33%). Despite a decline in melanoma diagnoses, Castle's investments in growth initiatives are reflected in these results. Year-end cash and equivalents are projected at $330 million.

Castle Biosciences, Inc. (Nasdaq: CSTL) announced that CEO Derek Maetzold and CFO Frank Stokes will present at the 24th Annual Needham Growth Conference on January 10, 2022, at 12:30 p.m. Eastern time. The presentation will be accessible via a live audio webcast on the company's website, with a replay available for two weeks thereafter. Castle Biosciences specializes in personalized diagnostics for diseases such as skin cancer and has an innovative test development pipeline aimed at improving treatment outcomes.

Castle Biosciences has announced the acquisition of Cernostics for approximately $30 million, with potential additional payments of up to $50 million based on milestones. This acquisition enables Castle to expand into the gastrointestinal market through the TissueCypher® Barrett’s Esophagus Assay, aimed at predicting high-grade dysplasia and esophageal cancer in Barrett’s esophagus patients. The deal is expected to add roughly $1 billion to Castle's U.S. total addressable market (TAM).

Castle Biosciences, Inc. (NASDAQ: CSTL) presented its DecisionDx® gene expression profile tests for skin cancer at the American Society for Dermatologic Surgery 2021 Annual Meeting (Nov. 19-21, 2021). These tests, including DecisionDx-Melanoma and DecisionDx-SCC, aim to enhance personalized treatment decisions and patient outcomes. Key findings indicated that integrating genetic data with clinical features can better predict metastasis and recurrence risks. The studies support the clinical utility of these tests in managing melanoma and cutaneous squamous cell carcinoma.